Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02262403
Other study ID # CHUB-HIRP-01
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 1, 2014
Est. completion date December 2021

Study information

Verified date February 2021
Source Brugmann University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of this study is to characterize the regulatory immune response induced by hookworm in an infected Vietnamese rural population from the periphery of HCM, evolution after infection treatment and during potential naturally reinfection.


Description:

Population: 20 healthy adults (18-65 years) infected and non infected by Hookworm will be recruited and treated according to Good Clinical Practice recommendations. Allergy will be excluded by skin prick tests. Amount and phenotype of Treg will be explored at several time points. Subsequent culture with environmental antigen will be performed on cryopreserved cells.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - 18-65 years old adults in good health status - To live in rural regions at risk of soil transmitted helminthes - Hookworm infection (infected group) - Uninfected by Hookworms (control group) Exclusion Criteria: - Pregnant woman - Positive allergic history - Auto-immune and/or HIV disease - Antihelminthics drug in the last 6 months and other current parasitic infection

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blood and feces sampling
Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.

Locations

Country Name City State
Vietnam Pham Ngoc Thach University of Medecine Ho Chi Minh City Distict 10

Sponsors (2)

Lead Sponsor Collaborator
Brugmann University Hospital Université Libre de Bruxelles

Country where clinical trial is conducted

Vietnam, 

References & Publications (4)

Finlay CM, Walsh KP, Mills KH. Induction of regulatory cells by helminth parasites: exploitation for the treatment of inflammatory diseases. Immunol Rev. 2014 May;259(1):206-30. doi: 10.1111/imr.12164. Review. — View Citation

Flohr C, Tuyen LN, Lewis S, Quinnell R, Minh TT, Liem HT, Campbell J, Pritchard D, Hien TT, Farrar J, Williams H, Britton J. Poor sanitation and helminth infection protect against skin sensitization in Vietnamese children: A cross-sectional study. J Allergy Clin Immunol. 2006 Dec;118(6):1305-11. Epub 2006 Oct 13. — View Citation

Flohr C, Tuyen LN, Quinnell RJ, Lewis S, Minh TT, Campbell J, Simmons C, Telford G, Brown A, Hien TT, Farrar J, Williams H, Pritchard DI, Britton J. Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. Clin Exp Allergy. 2010 Jan;40(1):131-42. doi: 10.1111/j.1365-2222.2009.03346.x. Epub 2009 Sep 15. — View Citation

Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol. 2013 Jun;13(6):461-7. doi: 10.1038/nri3464. Epub 2013 May 17. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other PBMC culture and cryopreservation Assessment of the orientation of the adaptative immune response to Dermatophagoides pteronyssinus.Subsequent Treg function testing and cell cultures (with environmental antigen) on cryopreserved PBMC (Peripheral Blood Mononuclear cells). after 12 weeks
Primary Amount and phenotype of Treg Four colors flow cytometry Treg measurements and phenotyping (FACSCantoII). 0-12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03278431 - Triple Combinations Against Hookworm Infections in Lao Phase 4
Completed NCT01717950 - Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults Phase 1
Completed NCT02143518 - Safety and Immunogenicity Study of Na-GST-1 With or Without CpG Phase 1
Completed NCT02126462 - Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults Phase 1
Completed NCT01261130 - Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults Phase 1
Completed NCT01385189 - Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant Phase 1
Terminated NCT00473967 - Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults Phase 1
Completed NCT00603889 - Development of a Skin Test for the Na-ASP-2 Hookworm Antigen N/A
Completed NCT02839161 - Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children Phase 1
Completed NCT02476773 - Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults Phase 1
Recruiting NCT01940757 - Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae Phase 1
Completed NCT00207753 - Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections N/A
Completed NCT03373214 - Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults Phase 1
Completed NCT00939198 - Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil N/A
Completed NCT00120081 - Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection Phase 1
Recruiting NCT05914363 - Evaluating Impact of Improved Floors on Health N/A